NCT04225208 - Pharmacokinetic and Mass Balance Study of Orally Administered [14C]-AZD4205 in Healthy Adult Male Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 6, 2020

Primary Completion Date

March 2, 2020

Study Completion Date

March 2, 2020

Conditions

Healthy Volunteers

Interventions

DRUG

[14C]-AZD4205, single 50 mg oral dose administrated on day 1

Each subject will receive 50 mg AZD4205 oral solution (free base equivalent) containing a nominal dose of 15 µCi \[14C\]- radiolabelled AZD4205 as a single administration .

Trial Locations (1)

21201

Pharmaron CPC, Baltimore